DG Peptide Protocols
Extensively StudiedSexual Health

Gonadorelin

GnRH

Gonadotropin-Releasing Hormone | GnRH Agonist

Half-life
2-4 minutes
Chain length
10 amino acids
Reference frequency
2-3 times weekly for fertility/TRT support; every 90-120 minutes for pulsatile therapy; single dose for diagnostic

Research overview

DoseGear research brief

Gonadorelin is a synthetic form of the naturally occurring gonadotropin-releasing hormone (GnRH). It stimulates the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn regulate testosterone production in men and ovulation in women. It is FDA-approved for diagnostic testing and fertility treatment. The pulsatile nature of GnRH secretion is critical for proper reproductive function.

Mechanism of action

Gonadorelin acts as an agonist of the GnRH receptor in the anterior pituitary. When administered in pulses (mimicking natural secretion patterns every 60-120 minutes), it stimulates release of FSH and LH. LH then stimulates Leydig cells in the testes to produce testosterone, or triggers ovulation in women. Continuous exposure paradoxically causes receptor downregulation and suppressed hormone production.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic version of endogenous gonadotropin-releasing hormone.

What it is researched for

Pituitary testing and reproductive-endocrine research through GnRH-receptor activation and LH/FSH release.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research contextAmountFrequencyRoute
Diagnostic testing100 mcgSingle injectionSubQ or IV
Fertility support50-100 mcg2-3x weeklySubQ
Pulsatile therapy5-20 mcg per pulseEvery 90-120 minSubQ pump
TRT adjunct100-200 mcg2-3x weeklySubQ

Reference cycle

Varies - diagnostic single use, fertility therapy ongoing, TRT support continuous

Reference storage

Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 14 days due to short stability

Safety context

Reported side effects

  • Injection site reactions
  • Headache
  • Flushing
  • Nausea
  • Abdominal discomfort

Contraindications & cautions

  • Hormone-sensitive tumors
  • Pregnancy
  • Hypersensitivity to GnRH or analogs
  • Conditions worsened by sex hormone release

Scientific references

  1. 01

    Gonadorelin in Hypogonadotropic Hypogonadism

    Scientific citationGonadorelin in Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology & Metabolism (2018).
  2. 02

    GnRH Pulsatility and Reproductive Function

    Scientific citationGnRH Pulsatility and Reproductive Function. Frontiers in Endocrinology (2020).
  3. 03

    Gonadorelin for Ovulation Induction

    Scientific citationGonadorelin for Ovulation Induction. Fertility and Sterility (2015).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles